BioTuesdays

Category - Markets

BeyondSpring Logo
Markets

HCW cuts BeyondSpring PT to $30 from $41

H.C. Wainwright lowered its price target for BeyondSpring (NASDAQ:BTSI) to $30 from $41, but reiterated a “buy” rating, citing a higher discount rate to account from increased uncertainty of COVID-19’s impact on...

March 30, 2020
Edesa Biotech
Markets

Brookline starts Edesa Biotech at buy; PT $10

Brookline Capital Markets launched coverage of Edesa Biotech (NASDAQ:EDSA) with a “buy” rating and $10 price target. The stock closed at $2.16 on March 27. Edesa is developing EB01, a topical sPLA2 inhibitor that...

March 30, 2020
AB Science Logo
Markets

HCW starts AB Science at buy; PT €9.00

H.C. Wainwright initiated coverage of AB Science (Euronext – FR0010557264 – AB) with a “buy” rating and price target of €9.00. The stock closed at €6.78 on March 27. AB Science’s lead product, masitinib, is...

March 30, 2020
PDS Biotechnology Logo
Markets

HCW cuts PDS Biotechnology to neutral; removes PT

H.C. Wainwright downgraded PDS Biotechnology (NASDAQ:PDSB) to “neutral” from “buy” and removed its price target, citing recent significant dilution and lack of meaningful catalysts over the remainder of the year “prompt...

March 30, 2020
soliton-logo
Markets

Roth starts Soliton at buy; PT $14

Roth Capital Partners launched coverage of Soliton (NASDAQ:SOLY) with a “buy” rating and $14 price target. The stock closed at $8.80 on March 26. Soliton is an aesthetic company that utilizes acoustic pulse technology...

March 27, 2020
Cipher Pharmaceuticals
Markets

Mackie cuts Cipher Pharma PT to $1 from $2.30

Mackie Research lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $1 (Canadian) from $2.30, citing a delay in the out-licensing of its Canadian assets because of a dispute with Bausch Health (NYSE:BHC)...

March 27, 2020
atyr Pharma
Markets

HCW cuts aTyr Pharma to neutral and removes PT

H.C. Wainwright downgraded aTyr Pharma (NASDAQ:LIFE) to “neutral” from “buy” and removed its price target, citing delays in topline results from a Phase 1b/2a trial of ATYR1923 for the treatment of sarcoidosis, an...

March 27, 2020
Eyenovia Logo
Markets

Ladenburg cuts Eyenovia PT to $19 from $30

Ladenburg Thalmann lowered its price target for Eyenovia (NASDAQ:EYEN) to $19 from $30, but reiterated its “buy” rating, reflecting dilution associated with a recent financing and anticipated additional dilution...

March 26, 2020